News
NVAX
--
0.00%
--
Pfizer And Moderna Face Their Biggest Challenge: Vaccinating The World
Investor's Business Daily · 1h ago
Novavax: Several Catalysts on the Horizon
Other “coronavirus stocks” might be further ahead in the development of their respective Covid-19 vaccines, but investors obviously feel Novavax (NVAX) is set to continue punching above its weight. Over the past month, shares have surged by 69%, adding to 2020’s barely believable gains -- 3,053% to be exact. Investors’ positive sentiment is echoed by B Riley analyst Mayank Mamtani. The analyst still expects Novavax to have a meaningful role in the global rollout of Covid-19 vaccines and reiterates a Buy rating on the stock. Mamtani’s $223 price target remains, too, and suggests possible upside of 77% from current levels. (To watch Mamtani’s track record, click here)Pfizer/BioNTech and Moderna have reported outstanding results from their candidates’ respective late stage studies, and they are expected to be granted EUAs (emergency use authorization) shortly. Despite lagging behind the competition, Novavax’ Covid-19 vaccine candidate has also been making some good progress.NVX-CoV2373 is currently in a Phase 3 trial in the U.K. and a phase 2b study in South Africa, both of which are now fully enrolled. While the U.S. & Mexico Phase 3 has been delayed, it is expected to kick off “in the coming weeks.”All could serve as near-term catalysts, according to Mamtani.An interim data readout from the U.K. study could get an airing possibly this month. The 5-star analyst expects NVX-CoV2373 to “demonstrate best-in-class VE & reactogenicity profile, thereby making the case for pursuing licensure across several nations globally in 1Q.”While the U.S Phase 3 data will only be available sometime in 2021 (possibly 1H), the late stage study’s initiation could serve as an “incremental catalyst before YE20.”Novavax could also get an additional boost from other programs’ vaccine data which did not quite attain the same lofty heights as Pfizer/BioNTech and Moderna’s offerings.“We anticipate incremental Ph. III mixed data updates noted with AZ as well as JNJ's single-dose JNJ-78436735 to possibly serve as tailwinds with NVAX's global supply scale-up efforts positioning it favorably to pick up significant demand share away particularly in 2022+ timeframe when demand wouldn't necessarily outpace supply in an effort to vaccinate several billions globally, likely on a recurring basis,” Mamtani summed up.Mamtani’s colleagues also anticipate further upside; Given the $179 average price target, the Street expects share gains of ~43% in the year ahead. The analyst consensus rates Novavax a Moderate Buy based on 3 Buys and 1 Sell. (See NVAX stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
TipRanks · 19h ago
Astra Data, Novavax Delay Spur Moderna Vaccine Demand, CEO Says
Confusion about AstraZeneca Plc’s Covid-19 vaccine data and delays in Novavax Inc.’s clinical trials are boosting demand worldwide for Moderna Inc.’s shot, according to that company’s chief executive officer.
Bloomberg · 1d ago
A New Surge in Cases Emphasizes the Need for Effective Diagnostics
, /PRNewswire/ -- As of earlier this week, the U.S. has reported more than 13.6 million cases and over 269,348 deaths, according to . Dr. of the National Institute of Allergy and Infectious Diseases, has also warned of "two to three thousand deaths a day times a couple of months, and you're approaching a really stunning number of deaths," Today . Because of the projected increase in the number of infected, states and cities are now planning new proposals and restrictions for the winter. For example, Governor announced his winter plan this Monday in case of another surge. The plan includes managing hospital capacity, adding beds, and identifying retired staff who can come back to work. In addition, Mayor, , has explained, according to , that "it's a call to arms. We need to make sure we never end up in a situation like we did in the spring and so much of that depends on individual behavior and really respecting the fact that we have to avoid any kind of large indoor gatherings," the Mayor said. "We have to ensure that people wear those masks, indoors and outdoors. These are the things that make a difference." Todos Medical Ltd. (OTC: TOMDF), Co-Diagnostics, Inc. (NASDAQ: CODX), OPKO Health company (NASDAQ: OPK), Novavax, Inc. (NASDAQ: NVAX), Pfizer Inc. (NYSE: PFE)
PR Newswire - PRF · 1d ago
As Biotech Thrives On Vaccine Hopes, Traders Look Into The Sector's Diversity
If there is one prevailing trend that Wall Street is counting on during this period of great economic and social uncertainty, it’s the promise of biotech and pharmaceutical companies to seemingly save the world.
Benzinga · 1d ago
North Korea-linked hackers targeted J&J, Novavax in hunt for COVID research
Suspected North Korean hackers have recently tried to break into at least nine health organizations, including pharmaceutical giant Johnson & Johnson and vaccine developer Novavax Inc, revealing a broader effort to target key players in the race to develop treatments for COVID-19. Four people who have investigated the attacks said the spate of hacking attempts began in September, and used web domains mimicking online login portals to try and trick staff at the targeted organisations into revealing their passwords. The hacking attempts included a bid to get inside British drugmaker and vaccine developer AstraZeneca, which Reuters first reported last week was in Pyongyang's crosshairs.
Reuters · 1d ago
N. Korean Hackers Said to Have Targeted at Least Six Companies Working on Covid-19 Treatments, Including Johnson & Johnson, Novavax, Three South Korean Companies
-Wall Street Journal https://www.wsj.com/articles/north-korean-hackers-are-said-to-have-targeted-companies-working-on-covid-19-vaccines-11606895026?mod=searchresults_pos1&page=1
Wall Street Journal · 1d ago
Novavax Inc Shares Up 33.7% Since SmarTrend's Buy Recommendation (NVAX)
SmarTrend identified an Uptrend for Novavax Inc (NASDAQ:NVAX) on November 9th, 2020 at $95.50. In approximately 3 weeks, Novavax Inc has returned 33.66% as of today's recent price of $127.65.
Comtex SmarTrend(R) · 2d ago
Trump Covid vaccine chief Slaoui says everyone in U.S. could be immunized by June
If enough people get immunized, the U.S. pandemic could be under control in the second half of 2021, the Trump administration's Covid vaccine chief said.
CNBC.com · 2d ago
Novavax (NVAX) Rises Despite U.S. Coronavirus Vaccine Study Delay
Novavax (NVAX) to begin a phase III study on NVX-CoV2373, its COVID-19 vaccine candidate in the United States and Mexico in the coming weeks. Shares up.
Zacks · 2d ago
Capri Holdings, Edgewell Personal Care, Moderna, Novavax and Zoom Video highlighted as Zacks Bull and Bear of the Day
Capri Holdings, Edgewell Personal Care, Moderna, Novavax and Zoom Video highlighted as Zacks Bull and Bear of the Day
Zacks · 2d ago
Thinking about trading options or stock in Novavax, Advanced Micro Devices, BioNTech, BP, or Tesla?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVAX, AMD, BNTX, BP, and TSLA.
PR Newswire - PRF · 2d ago
Markets Sell, November Overall Great; Plus ZM Q3 Beats
Market indexes were down on this last trading day of November, though it still managed to be an historically strong month for stocks overall.
Zacks · 2d ago
Is Novavax Stock A Buy As Pressure Mounts For A Covid-19 Vaccine?
Investor's Business Daily · 2d ago
COVID-19 Vaccine & Therapeutics Clinical Trial Analysis Report 2020: Regulatory Framework for COVID-19 Therapeutics and Vaccines Marketing Approvals
, /PRNewswire/ -- The report has been added to offering.  
PR Newswire - PRF · 3d ago
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
Zacks · 3d ago
Top Small Cap Stocks for December 2020
These are the small cap stocks with the best value, fastest growth, and most momentum for December 2020.
Investopedia · 3d ago
Dow Jones Down 400 Points But On Track For 11% Monthly Gain; Covid Stocks Rally
Investor's Business Daily · 3d ago
Coronavirus update: Moderna files for EUA; Novavax prepares for Phase 3
Positive vaccine news boosts sentiment as the country continues to report record hospitalizations.
Yahoo Finance · 3d ago
Return On Capital Employed Overview: Novavax
During Q3, Novavax's (NASDAQ: NVAX) reported sales totaled $157.02 million. Despite a 1039.03% in earnings, the company posted a loss of $193.94 million. In Q2, Novavax brought in $35.54 million in sales but lost $17.03 million in earnings.Why ROCE Is Significant Changes in earnings and sales indicate shifts in Novavax's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Novavax posted an ROCE of -0.63%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Novavax is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.For Novavax, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.Q3 Earnings Insight Novavax reported Q3 earnings per share at $-3.21/share, which did not meet analyst predictions of $1.73/share.See more from Benzinga * Click here for options trades from Benzinga * 12 Healthcare Stocks Moving In Monday's Pre-Market Session * 12 Healthcare Stocks Moving In Monday's Intraday Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 3d ago
Webull provides a variety of real-time NVAX stock news. You can receive the latest news about Novavax through multiple platforms. This information may help you make smarter investment decisions.
About NVAX
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
More